Related Experiment Video
Updated: May 10, 2025
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Adjuvant immunotherapy improves survival in completely resected stage IB-III NSCLC: a systematic review and
Hong Huang1, Pengchen Bao2, Hongyu Jin1
1Department of Pulmonary and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, China.
Background:
The clinical benefits of postoperative chemotherapy for non-small cell lung cancer (NSCLC) have plateaued, thus highlighting the need for novel strategies. This meta-analysis evaluated the efficacy and safety of adjuvant immunotherapy in patients with completely resected NSCLC and wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK).
Methods:
PubMed, Web of Science, Embase, and the Cochrane Library were searched up to February 12, 2025, for studies assessing adjuvant immunotherapy in NSCLC. Primary endpoints included disease-free survival (DFS), overall survival (OS), correlation between subgroup characteristics and efficacy, and safety outcomes, including treatment-related adverse events (TRAEs), severe adverse events (SAEs), and treatment discontinuation.
Results:
Twelve articles involving 4048 patients were included. Adjuvant immunotherapy significantly improved DFS in patients with resected stage IB-III NSCLC than supportive care or placebo (hazard ratio [HR]: 0.82, 95% confidence interval [CI]: 0.72-0.93, p = 0.01; I2 = 0%, p = 0.46). However, the OS benefit was not significant (HR: 0.9, 95% CI: 0.67-1.21, p = 0.34). DFS benefit was observed in EGFR-negative (HR: 0.75, 95% CI: 0.62-0.91, I2 = 0%), EGFR status unknown (HR: 0.78, 95% CI: 0.63-0.96, I2 = 0%), programmed cell death ligand 1 (PD-L1) 1-49% (HR: 0.75, 95% CI: 0.58-0.97, I2 = 7.13%), non-squamous cell carcinoma (HR: 0.72, 95% CI: 0.61-0.84, I2 = 0%), and never-smoking (HR: 0.68, 95% CI: 0.49-0.96, I2 = 0%) subgroups. The pooled incidences of TRAEs, SAEs, and discontinuation of treatment due to toxicity were 70% (95% CI: 62%-77%), 12% (95% CI: 8%-16%), and 17% (95% CI: 15-19%), respectively.
Conclusions:
Adjuvant immunotherapy improved DFS in patients with completely resected NSCLC, particularly those who were EGFR-negative, had PD-L1 levels of 1-49%, had non-squamous cell carcinoma, or never smoked.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024547752.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...